Preclinical evaluation of anti-HER2 2Rs15d nanobody labeled with 225Ac
Human Epidermal Growth Factor Receptor type 2 (HER2) is overexpressed in a series of human cancer types such as breast, ovarian, colorectal and urothelial carcinomas and is often associated with a higher recurrence rate and a shorter time to relapse. Intact mAbs are not always ideal vectors for radioimmunotherapy due to their slow pharmacokinetic and normal-tissue clearance. Nanobodies (nbs) are small antibody fragments (~15kDa) with beneficial pharmacokinetic properties, and those targeted to HER2 are very attractive vectors for targeted radionuclide therapy (TRT). The aim of this study was to develop and evaluate a potential molecular-targeted drug based on the anti-HER2-Nb labeled with 225Ac
PRUSZYNSKI Marek;
D’HUYVETTER Matthias;
CĘDROWSKA E;
LAHOUTTE Tony;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
2017-08-01
European Commission - Joint Research Centre
JRC105962
Additional supporting files
| File name | Description | File type | |
|---|
